1. Home
  2. TRNR vs ENVB Comparison

TRNR vs ENVB Comparison

Compare TRNR & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRNR

Interactive Strength Inc.

HOLD

Current Price

$0.62

Market Cap

3.0M

Sector

Technology

ML Signal

HOLD

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

HOLD

Current Price

$4.26

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNR
ENVB
Founded
2017
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.0M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
TRNR
ENVB
Price
$0.62
$4.26
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$120.00
AVG Volume (30 Days)
2.6M
53.6K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,774,000.00
N/A
Revenue This Year
$245.67
N/A
Revenue Next Year
$308.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
207.36
N/A
52 Week Low
$0.61
$3.50
52 Week High
$39.60
$61.18

Technical Indicators

Market Signals
Indicator
TRNR
ENVB
Relative Strength Index (RSI) 24.69 48.10
Support Level $0.64 $3.76
Resistance Level $1.62 $4.24
Average True Range (ATR) 0.15 0.28
MACD 0.00 0.08
Stochastic Oscillator 0.66 88.72

Price Performance

Historical Comparison
TRNR
ENVB

About TRNR Interactive Strength Inc.

Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: